Clinical trial

Ultra Curto (Ultra Short) TB Prevention Therapy

NCT04703075

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-03-24

PhasePHASE4

Study timeline

Study start (actual)2022-03-24Date precision: day

Registry last updated2025-06-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Tuberculosisunresolved

Interventions

Rifapentine 600 mg and INH 300 mgDRUG

Rifapentine 900 mg and INH 900 mgDRUG

Sponsors & collaborators

Johns Hopkins Universitylead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

Sanoficollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04703075 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.